It has previously been reported that 10058-F4 treatment leads to down-regulation of c-MYC protein levels in c-MYC overexpressing cell lines and we observed similar results for MYCN levels in MYCN-amplified NB cells [33], [34], [40]. Here, MYCN is linked to neuroblastoma.